OSI Pharmaceuticals President Colin Goddard: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Goddard talks about OSI’s metabolic syndrome pipeline, competing with Merck in the DPP-4 space and profitability.
You may also be interested in...
OSI Pharmaceuticals President Colin Goddard: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Goddard talks about OSI’s pipeline, dealing with competition from Pfizer and Genentech, and how he plans to “demonstrate a full year of profitability” in 2007.
Skin Toxicity Seen In Other DPP-4 Inhibitors Missing In Januvia NDA – FDA Review
FDA’s request for additional primate studies to assess potential skin toxicity stemmed from findings with other agents of the same class, agency review documents show.
Lilly Licenses OSI Glucokinase Activator Program For Type 2 Diabetes
The nearly $400 million deal gives Lilly exclusive rights to OSI’s GKA drugs, including a lead compound in Phase I studies.